Impact of cumulative cisplatin dose in childhood nasopharyngeal carcinoma based on neoadjuvant chemotherapy response in the intensity-modulated radiotherapy era: a real-world study

Table 3 Severe (grade 3–4) acute toxicity during concurrent chemotherapy and late toxicity during follow up

Adverse event	Entire cohort (n, %)	CC-CCD group (n, %)		P value^a
Adverse event	Entire cohort (n, %)	< 160 mg/m²	≥ 160 mg/m²	P value^a
Acute toxicity (n = 132)		n = 52	n = 80
Mucositis	57 (43.2)	21 (40.4)	36 (45.0)	0.719
Nausea	23 (17.4)	10 (19.2)	13 (16.3)	0.648
Leucopenia	35 (26.5)	14 (26.9)	21 (26.3)	0.996
Neutropenia	18 (13.6)	9 (17.3)	9 (11.3)	0.437
Anemia	5 (3.8)	1 (1.9)	4 (5.0)	0.648
Thrombocytopenia	2 (1.5)	1 (1.9)	1 (1.3)	0.997
Late toxicity (n = 115)		n = 43	n = 72
Xerostomia	11 (9.6)	5 (11.6)	6 (8.3)	0.723
Ototoxicity	9 (7.8)	4 (9.3)	5 (6.9)	0.726
Neck fibrosis	6 (5.2)	2 (4.7)	4 (5.6)	0.992
Hypothyroidism	3 (2.6)	2 (4.7)	1 (1.4)	0.555

CC-CCD cumulative cisplatin dose during concurrent chemoradiotherapy
^aP values were calculated using the chi-square test or Fisher exact test if indicated

ISSN: 1475-2867